...
首页> 外文期刊>Journal of Medical Case Reports >Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report
【24h】

Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report

机译:最初转移的直肠混合腺嘌呤内分泌癌的化学放疗长期控制:一例报告

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Abstract BackgroundMixed adenoneuroendocrine carcinomas are highly malignant tumors with both adenocarcinomatous and neuroendocrine components. They can originate in any organ but are more common in the rectum. Due to their rarity, current treatment recommendations for mixed adenoneuroendocrine carcinoma are based on limited data and follow general guidelines for the management of adenocarcinomas and neuroendocrine neoplasms. Uncertainty regarding the efficacy of the available local and systemic treatment strategies is a compounding issue. Even those patients with locally limited disease have a relatively short life expectancy. In this report, we describe a case of deep rectal mixed adenoneuroendocrine carcinoma with long survival after chemoradiation.Case presentationA 48-year-old Caucasian woman was diagnosed with a grade 3 rectal adenocarcinoma combined with a poorly differentiated large cell neuroendocrine carcinoma component and synchronous metastases (cT3cN1cM1) in both lobes of the liver in 2012. She received concomitant chemoradiotherapy followed by four additional cycles of cisplatin plus irinotecan. Initial treatment induced complete remission of the rectal tumor and liver metastases. Consequently, it was not necessary to surgically resect the primary tumor or any of the metastases. Three months after the end of treatment, one metastasis in the first segment of the liver showed regrowth, and stereotactic body radiotherapy of the metastasis and chemotherapy resulted in a clinical complete response. The patient has been recurrence-free for more than 5?years.ConclusionsExtended long-term control of a poorly differentiated metastatic (stage IV) mixed adenoneuroendocrine carcinoma is rare. The multimodal first- and second-line regimens of radiotherapy and chemotherapy described in this case report represent a new therapeutic approach. Encouraged by the results in this case, we compiled a review of the literature on mixed adenoneuroendocrine carcinoma.
机译:摘要背景混合的腺嘌呤神经内分泌癌是高度恶性的肿瘤,具有腺癌和神经内分泌成分。它们可以起源于任何器官,但更常见于直肠。由于它们的稀有性,目前针对混合腺嘌呤神经内分泌癌的治疗建议基于有限的数据,并遵循有关腺癌和神经内分泌肿瘤管理的一般指南。有关可用的局部和全身治疗策略疗效的不确定性是一个复杂的问题。即使是那些局部疾病有限的患者,其预期寿命也相对较短。在本报告中,我们描述了一例深部直肠混合腺嘌呤神经内分泌癌,放化疗后存活期长的病例。病例介绍一名48岁的白人妇女被诊断为3级直肠腺癌,并伴有分化不良的大细胞神经内分泌癌成分和同步转移。 (cT3cN1cM1)在2012年出现在肝脏的两个肺叶中。她接受了放化疗,随后又进行了四个顺铂加伊立替康的治疗。初始治疗可导致直肠肿瘤和肝转移完全缓解。因此,无需手术切除原发肿瘤或任何转移灶。治疗结束后三个月,肝脏第一部分的一个转移灶出现了再生长,转移的立体定向放疗和化学疗法导致了临床完全缓解。该患者已无复发5年以上。结论难于长期长期控制分化差的转移性(IV期)混合腺嘌呤内分泌癌。本病例报告中描述的多模式一线和二线放疗和化疗方案代表了一种新的治疗方法。在这种情况下,受结果的鼓舞,我们对有关混合腺嘌呤神经内分泌癌的文献进行了综述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号